login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
MEDICINOVA INC (MNOV) Stock News
NASDAQ:MNOV -
US58468P2065
-
Common Stock
1.31
USD
-0.03 (-2.24%)
Last: 8/29/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MNOV Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: MediciNova, Inc.
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
6 days ago - By: MediciNova, Inc.
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
a month ago - By: MediciNova, Inc.
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
a month ago - By: MediciNova, Inc.
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
a year ago - By: BusinessInsider
MNOV Stock Earnings: MediciNova Beats EPS for Q2 2024
a year ago - By: InvestorPlace
MNOV Stock Earnings: MediciNova Beats EPS for Q2 2024
a month ago - By: MediciNova, Inc.
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
a month ago - By: MediciNova, Inc.
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
5 months ago - By: MediciNova, Inc.
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
5 months ago - By: MediciNova, Inc.
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
5 months ago - By: MediciNova, Inc.
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
5 months ago - By: MediciNova, Inc.
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
9 months ago - By: MediciNova, Inc.
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
9 months ago - By: MediciNova, Inc.
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
9 months ago - By: Benzinga
- Mentions:
ADSK
ZTS
VKTX
PRCT
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
10 months ago - By: MediciNova, Inc.
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
10 months ago - By: MediciNova, Inc.
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
10 months ago - By: MediciNova, Inc.
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
10 months ago - By: MediciNova, Inc.
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
10 months ago - By: MediciNova, Inc.
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
10 months ago - By: MediciNova, Inc.
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
10 months ago - By: Benzinga
- Mentions:
CYCC
AZTR
DBVT
BIVI
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10 months ago - By: MediciNova, Inc.
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
10 months ago - By: MediciNova, Inc.
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
a year ago - By: MediciNova, Inc.
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
a year ago - By: MediciNova, Inc.
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
a year ago - By: MediciNova, Inc.
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
a year ago - By: MediciNova, Inc.
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
a year ago - By: MediciNova, Inc.
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
a year ago - By: MediciNova, Inc.
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
a year ago - By: MediciNova, Inc.
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
a year ago - By: MediciNova, Inc.
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
a year ago - By: MediciNova, Inc.
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
a year ago - By: MediciNova, Inc.
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
a year ago - By: MediciNova, Inc.
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
a year ago - By: MediciNova, Inc.
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
a year ago - By: MediciNova, Inc.
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
a year ago - By: MediciNova, Inc.
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
Please enable JavaScript to continue using this application.